v3.26.1
Significant Accounting Policies Additional Information (Details)
9 Months Ended 12 Months Ended
Mar. 31, 2026
USD ($)
SEGMENTS
shares
Mar. 31, 2025
shares
Jun. 30, 2025
USD ($)
shares
Jun. 30, 2024
USD ($)
shares
Significant Accounting Policies [Line Items]        
Uninsured cash balance $ 2,400,000   $ 8,000,000  
Deferred offering costs     $ 106,299
Expensed     20,000 0
Valuation allowance     103,434
Inventory write-down due to net realizable value     0 103,136
Inventory write-down due to obsolete     $ 0 208,737
Estimated useful life 18 years   18 years  
Impairment loss     $ 0 0
Accounts receivable     $ 1,952,363 $ 34,700
Antidilutive shares (in Shares) | shares 2,774,945 571,444 2,650,257 543,302
Reportable segment (in Segments) | SEGMENTS 1      
Operating segments (in Segments) | SEGMENTS 1      
BayMedica [Member]        
Significant Accounting Policies [Line Items]        
Severance costs $ 550,000      
Employee related costs $ 120,000      
Pre-Funded Warrants [Member]        
Significant Accounting Policies [Line Items]        
Antidilutive shares (in Shares) | shares 900,363 1,150,363    
Computer Equipment [Member]        
Significant Accounting Policies [Line Items]        
Estimated useful lives       5 years
Money Market Funds [Member]        
Significant Accounting Policies [Line Items]        
Cash equivalents $ 4,600,000   $ 4,479,809 $ 1,939,482
Minimum [Member] | Lab Equipment [Member]        
Significant Accounting Policies [Line Items]        
Estimated useful lives     6 years  
Maximum [Member] | Lab Equipment [Member]        
Significant Accounting Policies [Line Items]        
Estimated useful lives     10 years